

IARC Handbooks Volume 17 : Colorectal Cancer Screening

B Lauby-Secretan, N Vilahur and K Straif, on behalf of the Working Group for IARC Handbook Volume 17 (IHB Group / ESC Section – International Agency for Research on Cancer)

Background

Colorectal cancer (CRC) burden worldwide

- 3rd most common cancer in men and 2nd most common in women
- Almost 10% of the global cancer burden
- Incidence rates of CRC show a strong positive gradient with level of economic development
- Net five-year survival is around 60% in high-income countries; below 30% in the low-income countries in Asia and Africa.
- Risk factors: increased consumption of processed meat, alcoholic beverages, tobacco smoking, increased body fatness
- Protective factors: consumption of dietary fibre and dairy products, physical activity

Screening techniques evaluated

- **Stool-based blood tests:**
 - Guaiac-based faecal occult blood test (gFOBT), with or without rehydration
 - Faecal immunochemical test (FIT)
- **Endoscopic techniques:**
 - Flexible sigmoidoscopy
 - Colonoscopy
- **Emerging techniques:**
 - Computed tomographic colonography

Other topics covered

- Comparison of effects between stool-based blood tests and endoscopic techniques
- Other emerging techniques: capsule endoscopy, mt-sDNA, biomarkers in blood, urine or breath
- Determinants of participation in screening and interventions to increase participation
- Populations at an increased risk of colorectal cancer: genetic predisposition, family history of CRC, personal history of preneoplastic lesions or CRC

Evidence-based evaluations

Evaluations are based on a comprehensive review of the published scientific evidence.


The majority of randomized controlled trials and observational studies have been conducted:

- in middle- to high-income settings, where colorectal cancer incidence is generally high;
- in asymptomatic, average-risk populations aged 50–70 years on average;
- under conditions in which colorectal cancer screening – including subsequent follow-up and treatment – can be delivered with high quality.

Extrapolation of the conclusions to different settings needs to take into account these and other context-related specificities.

Knowledge dissemination

- ✓ **Dedicated website @ <http://handbooks.iarc.fr>**



- Information about upcoming, recent and past meetings
- Tables of all evaluations from Volumes 1 through 16
- Access to all Handbook volumes, available online as pdfs
- Poster presentations of recent meetings (HB15 and HB16)
- Working Procedures and other documentation related to the Handbooks

- ✓ **Brochure and flyers for funding requests**

- ✓ **Summary reports in the *New England Journal of Medicine* (Lauby-Secretan et al., 2015; 2016)**



Evaluations

The evaluation statements on the level of evidence for the effects of the different colorectal cancer screening procedures refer to a setting without colorectal cancer screening as a comparator.

Technique	Reduction in CRC incidence	Reduction in CRC mortality	Benefit-harm ratio	Evidence for beneficial and adverse effects
Biennial screening with gFOBT without rehydration	ESLE	S	S	+ Reduced colorectal cancer mortality, gain in quality-adjusted life years - Short-term psychological harms of screening per se or of a positive test, medical harms of follow-up colonoscopy after a positive test
Annual/biennial screening with gFOBT with increased sensitivity	L	S	S	+ Reduced colorectal cancer mortality and incidence, gain in quality-adjusted life years - Short-term psychological harms of screening per se or of a positive test, medical harms of follow-up colonoscopy after a positive test
Biennial screening with FIT	L	S	S	+ Reduced colorectal cancer mortality and incidence, gain in quality-adjusted life years - Short-term psychological harms of screening per se or of a positive test, medical harms of follow-up colonoscopy after a positive test
Single screening with flexible sigmoidoscopy	S	S	S	+ Reduced colorectal cancer incidence and mortality, gain in quality-adjusted life years - Short-term psychological harms of screening per se or of a positive test, infrequent procedural harms of sigmoidoscopy, medical harms of follow-up colonoscopy after a positive test
Single screening with colonoscopy	S	S	S / L *	+ Reduced colorectal cancer incidence and mortality, gain in quality-adjusted life years - Medical harms (bleeding, perforations), psychological harms of screening per se and of a positive test. ± Variability and related limited accuracy of the effect estimates, harms of colonoscopy, limitations in extrapolating from data of screening by flexible sigmoidoscopy
Single screening with CTC	L / I *		I	+ No direct evidence for a beneficial effect in reducing CRC incidence or mortality; test performances and adenoma detection rates similar to colonoscopy - Harms of ionizing radiation, uncertain harms and benefits of extracolonic findings, uncertainty when quantitative data of beneficial and adverse effects are lacking

S, sufficient evidence; L, limited evidence; I, inadequate evidence, ESLE, evidence suggesting lack of effect. *, denotes a minority view. CTC, computed tomography colonography; gFOBT, guaiac-based faecal occult blood test; FIT, faecal immunochemical test.

Summary report in the *New England Journal of Medicine* (Lauby-Secretan et al., 2018)

HB17 Working Group

Working Group members

Samar Alhomoud, Saudi Arabia
Johannes Blom, Sweden (Subgroup Chair, endoscopic techniques)
Michael Bretthauer, Norway
Jean-Luc Bulliard, Switzerland
Douglas Corley, USA
Montserrat Garcia Martinez, Spain
Michael Hoffmeister, Germany
Rolf Hultcrantz, Sweden

Iris Lansdorp-Vogelaar, The Netherlands
Iris Nagtegaal, The Netherlands
Paul Pinsky, USA (Overall Chair)
Linda Rabeneck, Canada (Subgroup Chair, Stool-based blood tests)
Suleeporn Sangrajrang, Thailand
Peter Sasieni, United Kingdom
Robert Smith, USA (Subgroup Chair, Emerging techniques and high-risk populations)
Robert Steele, United Kingdom

Joseph Sung, Hong Kong SAR
Carolina Wiesner Ceballos, Colombia (Subgroup Chair, Colorectal cancer and screening practices)
Ann Graham Zauber, USA

Invited Specialists
Josep M. Augé Fradera, Spain
Douglas Robertson, USA
Carlo Senore, Italy

International Agency for Research on Cancer



Staff of the IARC Handbooks



ACKNOWLEDGEMENTS

Financial support for the Handbooks was received from:
 o Institut National du Cancer (INCa), France
 o American Cancer Society, USA
 o Centers for Disease Control and Prevention, USA

We acknowledge the participation of Franca Bianchini (DKFZ, Germany) and Neela Guha (ESC/IMO) as rapporteurs during the meeting of HB17.

